Abstract
Background We report the transmission dynamics of SARS-CoV-2 across different settings from the first COVID-19 cluster in Brunei arising from a super-spreading event (SSE)—the Tablighi Jama’at religious gathering in Malaysia.
Methods Epidemiological and clinical information of all cases and close contacts were collected. All suspected cases and their close contacts were tested with RT-PCR, regardless of symptom presentation. Incubation period and serial interval (SI) were calculated. Attack rates (AR) and mean reproductive numbers were calculated for five different settings, and risk factors of infection were identified using log-binomial regression.
Findings Nineteen out of 75 identified Talbighi attendees in Brunei tested positive for SARS-CoV-2. They infected 52 other individuals, bringing the cluster size to 71. Among them, only 40 (56·3%) reported symptoms from diagnosis to discharge. Median incubation period is 4·5 days (IQR= 2·75) and mean SI is 4·26 days (SD= 4·27). Contact tracing identified 1755 contacts. The highest non-primary AR were observed at a local religious gathering (14·8% [95%CI: 7·1, 27·7]) and in the household (10·6% [95%CI: 7·3, 15·1]. Household ARs of symptomatic cases were higher (14·4% [95%CI: 8·8, 19·9]) than asymptomatic or presymptomatic cases (5·4% [95%CI: 1·2, 9·6]). Low ARs (<1%) were observed for workplace and social settings.
Interpretation Our analysis highlights that SARS-CoV-2 transmission varies depending on environmental, behavioural, and host factors. We identify ‘red flags’ of potential SSE development, and propose differentiated testing strategies that account for transmission risk.
Evidence before this study In an effort to curb the initial entry of COVID-19 and subsequent community spread, many countries have implemented various control measures, to varying levels of success. Models have estimated the basic reproductive number (R0) and many countries rely on this as a measure of transmission intensity. However, this does not account for variations in infectivity at the individual level. As such, current understanding of the drivers of SARS-CoV-2 transmission is limited particularly with respect to knowledge of the settings at highest risk, and targeted interventions that account for this.
Added value of this study We use a national-level contact tracing dataset to calculate the non-primary attack rates and the mean observed reproduction number across different settings (household, relatives, workplace, social, and local religious gathering). Our findings highlight the variability of SARS-CoV-2 transmission across different settings, identify settings at highest risk, and the role of environmental, behavioural, and host factors in driving SARS-CoV-2 transmission. Our study is the first to assess the setting-specific impact of asymptomatic transmission and we demonstrate that symptomatic cases are a driver of transmission.
Implications of all the available evidence Many countries that have imposed large-scale community lockdowns are developing strategies for de-escalation. We identify ‘red flags’ for the development of potential SSEs, for use by health authorities in risk assessment of mass gatherings and other events. We also propose differentiated testing strategies that account for transmission risk in persons with and without symptoms. Our analysis of transmission dynamics across different settings suggests that case isolation, contact tracing, and moderate physical distancing can be an effective approach to containment.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study does not receive any form of financial support.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Source of funding This study does not receive any form of financial support.
Conflict of interest None to be declared.
Data sharing statement De-identified participant data is available upon request to the corresponding author.
Data Availability
De-identified participant data is available upon request to the corresponding author.
